Promising Interim Phase I Data for miRisten in AML

AI SummaryClose X

Thalia reported promising interim Phase I results for miRisten in AML: nine relapsed/refractory patients (median age 55, range 27–79; 55% male; median four prior lines) have been treated, two dose levels completed and the third enrolling, with eight patients experiencing no dose-limiting toxicity; miRisten was immediately detectable on PK, reduced miR-126 and increased SPRED1, and patients showed reductions in leukemic blasts and neutrophil improvements including one transient complete response with neutrophil recovery persisting >1 year; topline Phase I readout is targeted for H1 2027 and City of Hope holds an equity interest and an exclusive licence via Thalia's US subsidiary.

Disclaimer*

UK 100

Latest directors dealings